Importance of therapeutic drug monitoring (TDM) of posaconazole in hematologic patients

Importance of therapeutic drug monitoring (TDM) of posaconazole in hematologic patients - Posa-TDM

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036219

Enrollment

100

Registered

2025-02-19

Start date

2025-02-10

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematology patients who have been treated with posaconazole

Interventions

Group 1: Determination of posaconazole level in hematologic patients treated with posaconazole i.v. or p.o.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hematology patients who have been treated with posaconazole

Exclusion criteria

Exclusion criteria: n.a.

Design outcomes

Primary

Measure	Time frame
Proportion of mirror measurements that are not within the target range	—

Secondary

Measure	Time frame
Risk factors for not reaching the target level	—

Countries

Germany

Contacts

Public ContactJohanna Kessel

Universitätsmedizin Frankfurt

johanna.kessel@ukffm.de069 6301 5452

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026